Stevanato Group Investor Relations

Founded in 1949, Stevanato Group is a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. The Group delivers an integrated, end-to-end portfolio of products, processes and services that address customer needs across the entire drug life cycle at each of the development, clinical and commercial stages. Stevanato Group’s core capabilities in scientific research and development, its commitment to technical innovation and its engineering excellence are central to its ability to offer value added solutions to clients.

Latest News

Stevanato Group to Participate in Upcoming Investor Conferences

View Press Release

Stevanato Group Reports Revenue of €280.0 Million for the Second Quarter of 2025

View Press Release

Stevanato Group Secures €200 Million in Financing from BNL BNP Paribas, Cassa Depositi e Prestiti, and Banco BPM to Fund Ongoing CAPEX Investments in Italy and the U.S.

View Press Release

Stevanato Group to Report Second Quarter 2025 Financial Results on August 5, 2025

View Press Release

Latest Financial Results

Q2 2025

Quarter Ended Jun 30, 2025

Earnings Release
PDF HTML
Audio
Earnings Webcast
Prepared Comments
PDF

We respect your privacy. We do not sell, rent, or loan any information to any third party.
Any information you give us is held with the utmost care and security, and will be used
only in ways indicated in our Privacy Policy.

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2024

Report Links

IR and Media Contacts

Company

Stevanato Group S.p.A.
Via Molinella 17
Piombino Dese, Padua 35017
Italy

Investor Relations

Lisa Miles
Chief Communications and Investor Relations Officer
lisa.miles@stevanatogroup.com

Giacomo Guiducci
Strategic Marketing and Investor Relations
giacomo.guiducci@stevanatogroup.com

Media

Team Lewis U.S.
T: +1 872 264 2546
stevanatous@teamlewis.com

Team Lewis Italy
T: +39 02 36531375
stevanatoita@teamlewis.com